U.S. Biotech Stock News

Argan stock has delivered an extremely strong run over the past three years, yet on the current checks it does not screen as a clear bargain and recent price weakness raises questions about how much valuation support remains. Argan has returned very roughly 12x over three years, which is a very large gain and leaves current holders asking how much of the story is already reflected in the share price. The key support for the valuation can come from the company continuing to convert its...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

We'd be surprised if First Community Corporation ( NASDAQ:FCCO ) shareholders haven't noticed that the Director of...

Cheesecake Factory (NasdaqGS:CAKE) reported record quarterly revenue above US$1b, with decade high margins. The company launched a new cheesecake flavor tied to a National Cheesecake Day campaign supporting Feeding America. The news combines a major sales milestone with a charitable initiative that connects brand visibility and social impact. Cheesecake Factory operates a large casual dining chain centered on full service restaurants and an extensive dessert offering. This mix positions...

AI driven hiring tools, virtual interviews and tighter rules around “social value” are reshaping how companies recruit, especially in the UK. That shift can help some stocks exposed to this trend and hurt others, depending on how they earn revenue and manage compliance pressure. If you care about where recruitment and workforce tech might fit in your portfolio, this screener offers a focused way to think about it. The rest of this article breaks down three stocks linked to these developments,...

Sanara MedTech Inc. ( NASDAQ:SMTI ), might not be a large cap stock, but it saw a significant share price rise of 68...

Gossamer Bio recently reported that, following a Pre-NDA Type B meeting with the FDA, it is preparing a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension, while also reacquiring worldwide rights to the drug and disclosing approximately US$57,000,000 in cash, cash equivalents and marketable securities as of June 30, 2026. An interesting angle is that the FDA flagged the strength of PROSERA’s results as review issues rather than filing issues, allowing Gossamer...

Dividend increase puts Hess Midstream’s cash returns in focus Hess Midstream (HESM) has drawn fresh attention after its board declared a quarterly cash distribution of $0.7888 per Class A share for the June 30, 2026 quarter, an increase of $0.0096 from the prior quarter. The payout is scheduled for August 14, 2026, to Class A shareholders of record on August 6, 2026. This gives income focused investors a clear date to watch and a concrete cash figure to evaluate. See our latest analysis for...

In the past week, Robert Half Inc. reported second-quarter 2026 results showing net income of US$26.32 million and diluted EPS of US$0.26, and issued third-quarter guidance calling for revenues of US$1.31 billion to US$1.41 billion and income per share of US$0.43 to US$0.53. Alongside these mixed results, the company pointed to stronger hiring intentions in its U.S. and Canadian surveys, underscoring ongoing demand for specialized talent solutions despite earlier earnings pressure. With...

Hotter, drier UK weather is putting fresh pressure on potato crops and crisp production costs, even as demand for snacks remains steady. That mix of rising input risks and resilient consumer appetite can matter a lot for packaged food stocks in 2026. Some companies may be better placed than others to handle higher irrigation expenses, crop variability and pricing decisions. This article looks at 3 stocks from our Consumer Staples, Packaged Foods & Snacks screener that appear positively...

Charles Schwab stock has delivered a 66.8% return over the past three years, and the current checks suggest the shares may still be pricing in less than the company’s full intrinsic value based on the Excess Returns model. At the same time, traditional earnings multiples point to a level that looks about right rather than deeply discounted. A 66.8% gain over three years puts Charles Schwab in focus for investors asking whether recent strength has already captured most of the...

Investors who take an interest in CVB Financial Corp. ( NASDAQ:CVBF ) should definitely note that the Independent...

We wouldn't blame Tenet Healthcare Corporation ( NYSE:THC ) shareholders if they were a little worried about the fact...

Some BancFirst Corporation ( NASDAQ:BANF ) shareholders may be a little concerned to see that the Non-Executive...

CBIZ stock has surged in recent weeks and now trades very close to the US$55 per share price implied in Grant Thornton Advisors' agreed all cash acquisition, while the company's broader valuation checks still suggest the shares lean cheap rather than stretched. Over the past 5 years CBIZ has delivered a total return of about 70%, which points to meaningful long term value creation for shareholders compared to shorter term swings. The proposed US$5b all cash takeover by Grant Thornton...

Outlook Therapeutics stock has had a very weak run over the past five years, yet recent FDA approval for its lead drug has put fresh attention on whether the current US$1.00 share price is justified given the broader valuation checks. The share price has declined 97.9% over the past five years, which means long term holders have absorbed very heavy losses that set a low base for any future rerating. The recent FDA approval of LYTENAVA for wet age related macular degeneration can support...

Sunrun stock is trading around US$9.47 after a very steep 82.3% decline over the past 5 years, and the valuation checks send a mixed message about whether that reset has gone far enough. Over 5 years, Sunrun shareholders have seen the share price fall 82.3%. This puts the current valuation in the context of a long and painful reset rather than a short term swing. Future demand for residential solar and Sunrun's ability to turn that demand into steady cash flows can support the current price...

Markets are searching for companies that can keep growing even as inflation, energy costs and central bank decisions pull in different directions. The Fast Growing Stocks With High Insider Ownership screener focuses on businesses where analysts and management see room for further expansion, and where insiders have meaningful skin in the game. That combination can appeal if you want growth that is supported by both external research and internal conviction. In this article you will see 3...

Amneal Pharmaceuticals (AMRX) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for additional strengths and vial sizes of its iohexol injection, which expands its radiographic contrast agent offering. See our latest analysis for Amneal Pharmaceuticals. The FDA approval arrives at a time when Amneal Pharmaceuticals’ share price momentum is strong, with a 30 day share price return of 10.47% and a year to date share price return of 50.87%, alongside a 1 year...

Tecnoglass stock has given shareholders a strong 150.1% return over the past 5 years, yet its recent slide and mixed valuation checks raise questions about how the current price stacks up against fundamentals. After a 40.9% decline over the past year and a year to date return that is down 13.8%, the focus now is whether the recent level around US$44.88 still offers value or mainly reflects past gains. Over 5 years Tecnoglass has returned 150.1%, which puts the recent share price weakness...

The latest Stellantis earnings update shows how quickly sentiment can swing when results and expectations do not line up. Net profit moved to €293 million in Q2 from a loss of €1.87 billion a year earlier, and adjusted operating income reached €773 million. However, the stock still fell as much as 8% on the day because the figure came in below the €914 million consensus. That kind of reaction can ripple across North American auto manufacturers. This article looks at 3 stocks exposed to that...

The Federal Trade Commission, Utah, and Los Angeles County filed a lawsuit against Hims & Hers Health (NYSE:HIMS) alleging unauthorized sharing of sensitive health data and deceptive billing practices. The complaint focuses on how the company handled patient information on its telehealth platform and how subscriptions and cancellations were billed and processed. The action highlights potential regulatory and reputational risks for Hims & Hers Health that investors may weigh when assessing...

The latest 1,000 point drop in the Dow after the Federal Reserve held interest rates steady has put value stocks back under the spotlight. With inflation still above target and U.S. oil prices near US$85 per barrel, many investors are taking a fresh look at large U.S. companies that already trade on lower price ratios and have some dividend history. This article focuses on three U.S. Large Cap Value Stocks from our screener that appear more directly exposed to the current rate and oil...

Michael Kneeland, former CEO and current non executive chairman of United Rentals, has joined the board of directors of NYSE:XPO. Kneeland brings leadership experience in industrial services, equipment rental and logistics related businesses. This appointment marks a recent change in XPO's board composition and governance structure. XPO operates in freight transportation and logistics, a sector that depends heavily on operational efficiency, capital discipline and consistent service...